Who are Brivaracetam bolus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Keppra, Oral levetiracetam, Topiramate Standard, Qudexy XR, Standard dose topiramate, Topiramate-Implant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brivaracetam-bolus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Brivaracetam bolus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brivaracetam bolus (Brivaracetam bolus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic agent; SV2A ligand. Area: Neurology.

phase 3 Antiepileptic agent; SV2A ligand SV2A (Synaptic Vesicle Protein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Brivaracetam bolus (Brivaracetam bolus) — UCB Pharma. Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand that modulates neurotransmitter release to reduce seizure activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brivaracetam bolus TARGET	Brivaracetam bolus	UCB Pharma	phase 3	Antiepileptic agent; SV2A ligand	SV2A (Synaptic Vesicle Protein 2A)
Keppra	levetiracetam	Generic (originally UCB Pharma)	marketed	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
Oral levetiracetam	Oral levetiracetam	Children's Hospital of Fudan University	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Topiramate Standard	Topiramate Standard	Janssen Korea, Ltd., Korea	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Qudexy XR	Qudexy XR	Upsher-Smith Laboratories	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Topiramate-Implant	Topiramate-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor, sodium channels, glutamate receptors

Recent regulatory actions (last 90 days)

2026-05-08 — Keppra · FDA · approved · US · Generic (originally UCB Pharma)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-03 — Keppra · 8163306 · Formulation · US
2027-10-31 — Keppra · 8431156 · Formulation · US
2027-10-31 — Keppra · 8470367 · Formulation · US
2028-09-17 — Keppra · 7858122 · Formulation · US
2031-06-07 — Keppra · 8802142 · Formulation · US
2031-12-07 — Keppra · 8802142*PED · Compound · US
2034-03-14 — Keppra · 11160786 · Formulation · US
2034-03-14 — Keppra · 9669009 · Method of Use · US
2034-03-14 — Keppra · 9339489 · Formulation · US

Sponsor landscape (Antiepileptic agent; SV2A ligand class)

UCB Pharma · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brivaracetam bolus — Competitive Intelligence Brief. https://druglandscape.com/ci/brivaracetam-bolus. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing